Wonride M2 FORTE Uses

Was this medicine useful for you?
sponsored

Wonride M2 FORTE indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Type 2 diabetes mellitus when diet, exercise and the single agent (Wonride M2 FORTE) do not result in adequate glycaemic control.

Wonride M2 FORTE description

Each tablet contains Glimepiride (Wonride M2 FORTE) 2 mg and Metformin (Wonride M2 FORTE) HCl (in sustained-release form) 500 mg.

It also contains the following excipients: Hypromellose, sodium carboxymethyl cellulose, methacrylic acid copolymer dispersion, macrogol, povidone, magnesium stearate, purified water, sodium starch glycolate, lactose, titanium dioxide, microcrystalline cellulose, magnesium stearate and pregelatinized starch. Colors: Yellow ferric oxide and titanium dioxide.

Wonride M2 FORTE dosage

In principle, the dosage of Wonride M2 FORTE is governed by the desired blood glucose level. The starting dose of Wonride M2 FORTE is 1 tab once a day before or with breakfast or first main meal. The dosage of Wonride M2 FORTE must be the lowest which is sufficient to achieve the desired metabolic control.

During treatment with Wonride M2 FORTE, glucose levels in blood and urine must be measured regularly. In addition, it is recommended that regular determinations of the proportion of glycated haemoglobin be carried out.

Mistakes eg, forgetting to take a dose, must never be corrected by subsequently taking a larger dose.

Measures for dealing with such mistakes (in particular, forgetting a dose or skipping a meal) or situations where a dose cannot be taken at the prescribed time must be discussed and agreed between physician and patient beforehand.

As an improvement in control of diabetes is, in itself, associated with higher insulin sensitivity, Glimepiride (Wonride M2 FORTE) requirements may fall as treatment proceeds. To avoid hypoglycaemia, timely dose reduction or cessation of Wonride M2 FORTE therapy must therefore be considered.

The highest recommended dose per day should be Glimepiride (Wonride M2 FORTE) 8 mg and Metformin (Wonride M2 FORTE) 2000 mg.

Daily doses of Glimepiride (Wonride M2 FORTE) of >6 mg are more effective only in a minority of patients.

In order to avoid hypoglycaemia, the starting dose of Wonride M2 FORTE should not exceed the daily doses of Glimepiride (Wonride M2 FORTE) or Metformin (Wonride M2 FORTE) already being taken.

When switching from combination therapy of Glimepiride (Wonride M2 FORTE) plus Metformin (Wonride M2 FORTE) as separate tablets, Wonride M2 FORTE should be administered on the basis of dosage currently being taken.

Titration: The daily dose should be titrated in increments of 1 tab only, corresponding to the lowest strength (in case various strengths are available).

Duration of Treatment: Treatment with Wonride M2 FORTE is normally a long-term therapy.

Administration: Wonride M2 FORTE should be administered once per day during breakfast or at the first main meal. Due to the sustained-release formulation, Wonride M2 FORTE must be swallowed whole and not crushed or chewed.

Wonride M2 FORTE interactions

sponsored

Cimetidine: Metformin (Wonride M2 FORTE) interacts with cimetidine. Therefore, the dose of Metformin (Wonride M2 FORTE) should be reduced if cimetidine is co-prescribed.

Hyperglycemic Agents: Drugs with hyperglycemic potential (eg, thiazides, corticosteroids and others) may partly offset the antihyperglycemic action of Metformin (Wonride M2 FORTE), and in such cases, the glycemic control should be closely monitored.

Alcohol: Alcohol potentiates the action of Metformin (Wonride M2 FORTE) on lactate metabolism as well as the antihyperglycemic effect. Hence, patients treated with Metformin (Wonride M2 FORTE) should preferably avoid alcohol and alcoholism is a definite contraindication.

Other Interactions: Studies with furosemide and nifedipine suggest a possible interaction by increasing plasma Metformin (Wonride M2 FORTE) levels. However, no such changes were found with propranolol and ibuprofen.

The absorption of Metformin (Wonride M2 FORTE) may be reduced by acarbose and guar gum. Hypoglycemia due to interaction with Glimepiride (Wonride M2 FORTE) may occur when one of the following medicines is taken eg, insulin and other oral antidiabetics, angiotensin-converting enzymes (ACE) inhibitors, allopurinol, anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine, guanethidine, isofamide, monoamine oxidase (MAO) inhibitors, miconazole, para-aminosalicylic acid, pentoxifylline (high-dose parenteral), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolones, salicylates, sulfinpyrazone, sulfonamides, tetracyclines, tritoqualine, trofosfamide. Hyperglycemia due to interaction with Glimepiride (Wonride M2 FORTE) may occur when one of the following medicines is taken eg, acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine (adrenaline) and other sympathomimetic agents, glucagons, laxatives (after protracted use), nicotinic acid (in high doses), estrogens and progestogens, phenothiazines, phenytoin, rifampicin, thyroid hormones. H2-receptor antagonists, clonidine and reserpine may lead to either potentiation or weakening of the blood sugar-lowering effect. Beta-blockers may increase the tendency to hypoglycemia.

The effect of coumarin derivatives may be potentiated or weakened.

Wonride M2 FORTE side effects

sponsored

Metformin (Wonride M2 FORTE) may provoke or augment lactic acidosis particularly if it is present in high concentrations in the blood. Some of the symptoms of lactic acidosis may mimic certain adverse effects of Metformin (Wonride M2 FORTE).

Physicians should instruct their patients to recognize the onset of symptoms of lactic acidosis to avoid this adverse reaction.

There is a great potential risk for hypoglycemia to occur due to the sulfonylurea component of Wonride M2 FORTE.

Possible symptoms include headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, impaired alertness and reactions, depression, confusion, speech disorders, aphasia, visual disorders, tremor, pareses, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence, and loss of consciousness up to and including coma, shallow respiration and bradycardia.

Reported Adverse Events to Metformin (Wonride M2 FORTE) are as Follows: Gastrointestinal: Adverse effects appear to be dose-related and include diarrhea, nausea, vomiting, abdominal discomfort (eg, abdominal cramps or pain), abnormal stools, constipation, abdominal distention, dyspepsia, epigastric discomfort, flatulence, viral gastroenteritis, taste disturbance specifically metallic taste in the mouth, toothache, tooth abscess. Most of these reactions are transient and can be controlled by taking Metformin (Wonride M2 FORTE) with meals or by a temporary reduction in dosage.

Body as a Whole: Chills, flu syndrome, fatigue, lethargy, asthenia, accidental injury, headache, infection

Cardiovascular: Chest discomfort/pain, hypertension, palpitations

Hematologic: Vitamin B12 and folate malabsorption, thrombocytopenia, neutropenia and rare reports of megaloblastic anemia

Hepatic: Severe acute hepatitis associated with liver function tests abnormalities and cholestasis have been associated with long-term Metformin (Wonride M2 FORTE) therapy resolving upon discontinuation of Metformin (Wonride M2 FORTE).

Endocrine Effects: Hypoglycemia may occur when Metformin (Wonride M2 FORTE) is given concomitantly with sulfonylureas and/or alcohol; hyperglycemia (NOS) and sexual dysfunction.

Musculoskeletal: Asthenia, muscle cramp, muscle strain, myalgia, pain in limb.

Nervous System: Agitation, dizziness, migraine, paresthesia, syncope, sinus headache, hypoesthesia, lightheadedness, tremor.

Respiratory: Dyspnea, flu syndrome, nasal congestion, sinus congestion, rhinorrhea, rhinitis, tonsillitis, upper respiratory infection.

Skin and Appendages: Rash, erythema, pruritus, urticaria, increased sweating, contusion.

Others: Pneumonitis with vasculitis, aggravated edema, peripheral edema, ear pain, blurred vision, fungal infection, flushing, nail disorder and seasonal allergy.

The profile of adverse reactions in pediatric patients is similar to those observed in adults.

Laboratory Findings: Decreased blood glucose, abnormal liver function tests and increased white blood cell count.

Reported Adverse Events to Glimepiride (Wonride M2 FORTE) are as Follows: Metabolic-Nutritional: Hypoglycemia, hyperglycemia, hyponatremia, increased appetite, dyspepsia, anorexia.

Gastrointestinal (GI): Diarrhea, nausea, vomiting, abdominal discomfort, abdominal distention, sensation of fullness.

Cardiovascular: Hypertension, tachycardia, bradycardia, palpitations, angina pectoris, cardiac arrhythmias, vasodilation.

Hematologic: Hemolytic and aplastic anemia, leukopenia, agranulocytosis, thrombocytopenia, thrombocytopenic purpura, pancytopenia due to myelosuppression, eosinophilia, erythrocytopenia, granulocytopenia.

Central Nervous System: Disulfiram-like reactions, headache, dizziness, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, alertness and reaction time, depression, confusion, aphasia, tremor, paresis, sensory disturbance, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence and loss of consciousness up to and including coma.

Hepatobiliary: Cholestasis, jaundice, abnormal liver function, hepatitis which may lead to liver failure or hepatic dysfunction, hepatic porphyria reactions, increased liver enzyme levels, granulomatous hepatitis, bilirubinemia.

Skin and Subcutaneous Tissue Disorders: Allergic or pseudo-allergic skin reactions (eg, pruritus, erythema, urticaria, vasculitis, and morbilliform or maculopapular eruptions). Such mild reactions may develop into serious reactions with dyspnea and hypotension, sometimes progressing to shock. These may be transient and may disappear despite continued use of Glimepiride (Wonride M2 FORTE). If skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda, photosensitivity reactions and clammy skin were also observed.

Miscellaneous: Asthenia, allergic vasculitis, sweating, impaired speech disorder, visual disturbance/abnormal vision, dyspnea, increased urinary frequency.

Wonride M2 FORTE contraindications

sponsored

Patients hypersensitive to Glimepiride (Wonride M2 FORTE), Metformin (Wonride M2 FORTE), other sulfonylureas, other sulfonamides or any of the excipients of Wonride M2 FORTE.

Glimepiride (Wonride M2 FORTE): No experience has been gained concerning the use of Glimepiride (Wonride M2 FORTE) in patients with severe impairment of liver function and in dialysis patients. In patients with severe impairment of hepatic function, changeover to insulin is indicated, not least to achieve optimal metabolic control.

Metformin (Wonride M2 FORTE): Diabetic ketoacidosis, diabetic pre-coma.

Renal failure or renal dysfunction (eg, serum creatinine levels >135 micromol/L in males and >110 micromol/L in females).

Acute conditions with the potential to alter renal function eg, dehydration, severe infection, shock, intravascular administration of iodinated contrast agents.

Acute or chronic disease which may cause tissue hypoxia eg, cardiac or respiratory failure, recent myocardial infarction, shock.

Hepatic insufficiency; acute alcohol intoxication, alcoholism.

Use in pregnancy & lactation: Glimepiride (Wonride M2 FORTE): Glimepiride (Wonride M2 FORTE) must not be taken during pregnancy. Otherwise, there is risk of harm to the child. The patient must changeover to insulin during pregnancy.

Patients planning a pregnancy must inform their physician. It is recommended that such patients changeover to insulin.

To prevent possible ingestion with the breast milk and possible harm to the child, Glimepiride (Wonride M2 FORTE) must not be taken by breastfeeding women. If necessary, the patient must changeover to insulin or must stop breastfeeding.

Metformin (Wonride M2 FORTE): To date, no relevant epidemiological data are available. Animal studies do not indicate harmful effects with respect to pregnancy, embryonal or fetal development, parturition or postnatal development.

When the patient plans to become pregnant and during pregnancy, diabetes should not be treated with Metformin (Wonride M2 FORTE) but insulin should be used to maintain blood glucose levels as close to normal as possible in order to lower the risk of fetal malformations associated with abnormal blood glucose levels.

Metformin (Wonride M2 FORTE) is excreted into milk in lactating rats. Similar data are not available in humans and a decision should be made whether to discontinue nursing or to discontinue Metformin (Wonride M2 FORTE), taking into account the importance of the compound to the mother.



Active ingredient matches for Wonride M2 FORTE:

Glimepiride/Metformin


Unit description / dosage (Manufacturer)Price, USD
WONRIDE M2 FORTE TABLET 1 strip / 10 tablets each (Wonset Healthcare Pvt. Ltd.)$ 1.27

List of Wonride M2 FORTE substitutes (brand and generic names):

ZENOGLIM M2 2 MG/500 MG TABLET 1 strip / 10 tablets each (Zenvita Healthcare Pvt Ltd)$ 1.44
ZETAGLIM M 1MG/500MG TABLET 1 strip / 10 tablets each (Elinor Pharmaceuticals Pvt Ltd)$ 0.73
ZETAGLIM M 1MG TABLET 1 strip / 10 tablets each (Elinor Pharmaceuticals Pvt Ltd)$ 0.73
ZETAGLIM M 2MG TABLET 1 strip / 10 tablets each (Elinor Pharmaceuticals Pvt Ltd)$ 0.98
Zetaglim M 1mg Tablet (Elinor Pharmaceuticals Pvt Ltd)$ 0.08
Zetaglim M 2mg Tablet (Elinor Pharmaceuticals Pvt Ltd)$ 0.10
Ziglim M 2+500 Tablet (FDC Limited)$ 0.05
Ziglim M 1+500 Tablet (FDC Limited)$ 0.03
Ziglim M 1mg/500mg Tablet SR (FDC Limited)$ 0.05
ZIGLIM-M 1 MG/500 MG TABLET SR 1 strip / 10 tablet srs each (FDC Ltd)$ 0.51
ZIGLIM-M 2 MG/500 MG TABLET SR 1 strip / 10 tablet srs each (FDC Ltd)$ 0.76
ZORGLIM M 1MG TABLET 1 strip / 10 tablets each (Instanz Life Sciences Pvt Ltd)$ 0.76
ZORGLIM M 2MG TABLET 1 strip / 10 tablets each (Instanz Life Sciences Pvt Ltd)$ 1.10
Zorglim M 2mg/500mg Tablet (Instanz Life Sciences Pvt Ltd)$ 0.11
Zoryl M Capsule/ Tablet / 1mg-500mg / 10 units (Intas Laboratories Pvt Ltd)$ 0.71
Zoryl M Capsule/ Tablet / 2mg-500mg / 10 units (Intas Laboratories Pvt Ltd)$ 0.97
Zoryl M Glimepiride 2mg, Metformin500mg TAB / 10 (Intas Laboratories Pvt Ltd)$ 0.79
Zoryl M Glimepiride 1mg, Metformin500mg TAB / 10 (Intas Laboratories Pvt Ltd)$ 0.56
10's (Intas Laboratories Pvt Ltd)$ 0.56
Zoryl M 2+500 Tablet (Intas Laboratories Pvt Ltd)$ 0.10
Zoryl M 1+500 Tablet (Intas Laboratories Pvt Ltd)$ 0.08
ZORYL M 0.5 MG/500 MG TABLET 1 strip / 15 tablets each (Intas Laboratories Pvt Ltd)$ 0.59
ZORYL M 1 MG/500 MG TABLET SR 1 strip / 15 tablet srs each (Intas Laboratories Pvt Ltd)$ 1.59
ZORYL M - 2 FORTE TABLET 1 strip / 10 tablets each (Intas Laboratories Pvt Ltd)$ 1.44
ZORYL M 3 MG/500 MG TABLET SR 1 strip / 10 tablet srs each (Intas Laboratories Pvt Ltd)$ 1.68
ZORYL M 4 MG/500 MG TABLET SR 1 strip / 10 tablet srs each (Intas Laboratories Pvt Ltd)$ 2.24
ZORYL M FORTE 1 MG/1000 MG TABLET 1 strip / 10 tablets each (Intas Laboratories Pvt Ltd)$ 1.07
ZORYL M FORTE 3 MG/1000 MG TABLET 1 strip / 10 tablets each (Intas Laboratories Pvt Ltd)$ 1.65
ZORYL M FORTE 4 MG/1000 MG TABLET 1 strip / 10 tablets each (Intas Laboratories Pvt Ltd)$ 2.07
Zoryl M 0.5 Tablet (Intas Laboratories Pvt Ltd)$ 0.04
Zoryl M 1 Forte Tablet SR (Intas Laboratories Pvt Ltd)$ 0.12
Zoryl M 1 Tablet ER (Intas Laboratories Pvt Ltd)$ 0.12
Zoryl M 2 Tablet ER (Intas Laboratories Pvt Ltd)$ 0.16
Zoryl M 3 Forte Tablet SR (Intas Laboratories Pvt Ltd)$ 0.18
Zoryl M 3mg/500mg Tablet SR (Intas Laboratories Pvt Ltd)$ 0.18
Zoryl M 4 Forte Tablet SR (Intas Laboratories Pvt Ltd)$ 0.21
Zoryl-M Glimepiride 2 mg, Metformin500 mg. TAB / 10 (Intas)$ 0.79
Zoryl-M Metformin 500 mg, Glimepiride1 mg TAB / 10 (Intas)$ 1.26
ZORYL-M 2 TABLET 1 strip / 15 tablets each (Intas)$ 2.22
ZORYL-M tab 15's (Intas)$ 1.87
ZORYL-M film-coated tab 15's (Intas)$ 1.34
ZORYL-M tab 10's (Intas)$ 1.89
Zoryl-M Forte Glimepiride 1 mg, Metformin 1g. TAB / 10 (Intas)$ 0.72

References

  1. DailyMed. "GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "metformin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. PubChem. "glimepiride". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Wonride M2 FORTE are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Wonride M2 FORTE. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved